Hypothermia inhibits translocation of CaM kinase II and PKC-?, ?, ? isoforms and fodrin proteolysis in rat brain synaptosome during ischemia-reperfusion

2002 ◽  
Vol 67 (5) ◽  
pp. 664-669 ◽  
Author(s):  
Kazuki Harada ◽  
Tsuyoshi Maekawa ◽  
Ryosuke Tsuruta ◽  
Tadashi Kaneko ◽  
Daikai Sadamitsu ◽  
...  
2015 ◽  
Vol 117 (suppl_1) ◽  
Author(s):  
Johannes Backs ◽  
Tao He ◽  
Lorenz H Lehmann ◽  
Andrea Schmidt ◽  
Jan Beckendorf ◽  
...  

CaM Kinase II (CaMKII) critically drives adverse cardiac remodeling. During the process of remodeling, CaMKII binds and phosphorylates Histone Deacetylase 4 (HDAC4), resulting in activation of the transcription factor MEF2. However, it remained unclear whether binding between CaMKII and HDAC4 causes heart failure and whether this interaction represents a novel therapeutic target. We used mouse genetics, HDAC4-based peptides and chemical biology to address these questions. First, we generated CaMKII-resistant HDAC4 mutant mice (CrH) by replacing Arg-598 (corresponds to Arg-601 in humans) of HDAC4 with Phe, because we found Arg-598 to be essential for the CaMKII-HDAC4 interaction. CrH were protected from cardiac dysfunction, hypertrophy and fibrosis in response to both pathological pressure overload or ischemia/reperfusion injury. CrH showed reduced CaMKII binding and less MEF2 activation. These data provided a proof-of-principle that the disruption of the CaMKII-HDAC4 interaction may have therapeutic potential. Thus, in a second step we engineered an HDAC4-derived peptide with homology to the CaMKII binding domain of HDAC4. This peptide competed with HDAC4 for binding with CaMKII, resulting in decreased MEF2 activation and attenuated agonist-induced cardiomyocyte hypertrophy. These data encouraged us to carry the translational pipeline one step further and we screened for small molecules that disrupt the CaMKII-HDAC4 interaction in an in vitro ALPHAScreen Assay (medium-throughput format using 78000 compounds). After a stringent validation process, 38 compounds showed > 40% inhibition. Out of these, 13 compounds effectively inhibited MEF2 activity in a cell-based assay without obvious signs for cellular toxicity, providing now potential cell permeable drug-like candidates. Chemical optimization and in vivo validation strategies are currently ongoing. In summary, we show that the CaMKII-HDAC4 interaction contributes to the development of heart failure and we identified drug-like molecules that specifically disrupt this protein-protein interaction. These findings lay the ground for a novel epigenetic therapeutic approach to combat heart failure.


2007 ◽  
Vol 28 (9) ◽  
pp. 1388-1395 ◽  
Author(s):  
Daniela Tardito ◽  
Massimo Gennarelli ◽  
Laura Musazzi ◽  
Raffaella Gesuete ◽  
Stefania Chiarini ◽  
...  

2009 ◽  
Vol 65 ◽  
pp. S70
Author(s):  
Shigeki Moriguchi ◽  
Feng Han ◽  
Norifumi Shioda ◽  
Satomi Kita ◽  
Issei Komuro ◽  
...  

1999 ◽  
Vol 19 (6) ◽  
pp. 667-672 ◽  
Author(s):  
Shunya Takizawa ◽  
Naoto Fukuyama ◽  
Hisayuki Hirabayashi ◽  
Hiroe Nakazawa ◽  
Yukito Shinohara

The purpose of this study was to establish the dynamics of nitrotyrosine (NO2-Tyr) formation and decay during the rise of NO2-Tyr in rat brain subjected to 2-hour focal ischemia-reperfusion, and to evaluate the role of inducible nitric oxide synthase in the rise. The authors first determined the half life of NO2-Tyr in rat brain at 24 hours after the start of reperfusion by blocking NO2-Tyr formation with NG-monomethyl-l-arginine and after the decay of NO2-Tyr by means of a hydrolysis/HPLC procedure. The values obtained were approximately 2 hours in both peri-infarct and core-of-infarct regions. Using the same hydrolysis/HPLC procedure, the ratio of nitrotyrosine to tyrosine from the 2-hour occlusion to as much as 72 hours after the start of reperfusion was measured in the presence and absence of aminoguanidine (100 mg/kg intraperitoneally twice a day). In the absence of aminoguanidine, the ratio of NO2-Tyr in the peri-infarct and core-of-infarct regions reached 0.95% ± 0.34% and 0.52% ± 0.34%, respectively, at 1 hour after the start of reperfusion, The elevated levels persisted until 48 hours, then declined, The peri-infarct region showed the highest percent NO2-Tyr level, followed by the core of infarct, then the caudoputamen, Aminoguanidine significantly reduced NO2-Tyr formation (up to 90% inhibition) during 24 to 48 hours, The authors conclude that inducible nitric oxide synthase is predominantly responsible for NO2-Tyr formation, at least in the late phase of reperfusion, These results have important implications for the therapeutic time window and choice of nitric oxide synthase inhibitors in patients with cerebral infarction.


2002 ◽  
Vol 138 (2) ◽  
pp. 97-107 ◽  
Author(s):  
Cécile Pinaudeau-Nasarre ◽  
Afsaneh Gaillard ◽  
Michel Roger

1997 ◽  
Vol 237 ◽  
pp. S39
Author(s):  
A. Peretz ◽  
I. Abitbol ◽  
C.F. Wu ◽  
B. Attali

Sign in / Sign up

Export Citation Format

Share Document